Challenges in medical algorithmic fairness

Abstract

Artificial intelligence (AI) is increasingly being integrated into oncology for applications including cancer detection, risk stratification, treatment planning, and clinical documentation. Concerningly, growing evidence demonstrates that AI systems can reproduce or amplify existing disparities across patient populations. Although considerable effort has focused on developing computational methods to reduce algorithmic bias, many challenges surrounding fairness extend beyond technical implementation. In this commentary, we examine algorithmic fairness in oncology from both technical and normative perspectives. We review common sources of bias throughout the machine learning pipeline, discuss major statistical definitions of fairness, including demographic parity, calibration, and equalized odds, and highlight the inherent trade-offs among these metrics. We further explore how fairness often conflicts with overall predictive performance, arguing that model selection inevitably reflects ethical judgments rather than purely technical optimization. We discuss the limitations of current bias mitigation strategies and contend that many disparities rooted in historical and structural inequities cannot be resolved through algorithmic interventions alone. Finally, we outline priorities for the responsible development and deployment of clinical AI, including greater transparency in fairness decisions, context-specific evaluation standards, ongoing post-deployment auditing, and stronger regulatory oversight. Achieving equitable AI in oncology will require coordinated efforts among developers, clinicians, regulators, and patients to ensure that these technologies improve outcomes without perpetuating existing inequities.